Biotech Stocks Surge Higher, Breaking Out

This column is my opinion and expresses my views. Those views can change at a moments notice when the market changes. I am not right all the time and I do not expect to be. I disclose all my positions clearly listed on the page, and I do not trade my account on the stocks spoken of in this column unless fully disclosed. If that does not work for you stop reading and close the page. Do not bother me or harass me.

Otherwise, enjoy the column!

Subscribe to the Monster Stock Market Commentary to get the Weekly Monster Market Commentary and join the 3,136 subscribers getting it for FREE!

This Daily Commentary Is Availabe For $99 Per Year, Sign Up!

Biotech Breakout

Biotech stocks just took another step higher, clearing its latest hurdle. The Nasdaq IBB ETF today broke above the $320 level, moving higher by about 1.5 percent. The next resistance level takes the ETF to around the $340 level from here.

Biotech Chart IBB

(Interactive Brokers)

The breakout seems significant and its is spilling over the names within the group. You can see in the table below there are only 3 stocks that are lower on the day.


Biotech Holdings stocks

(Data compiled using Ycharts)



Subscribe to the MCM Stock Market Commentary to get it weekly and join the 3,136 subscribers getting it for FREE!

Michael Kramer is the Founder of Mott Capital Management LLC, a registered investment adviser, and the manager of the company’s actively managed, long-only Thematic Growth Portfolio. Information presented is for educational purposes only and does not intend to make an offer or solicitation for the sale or purchase of any specific securities, investments, or investment strategies. Investments involve risk and unless otherwise stated, are not guaranteed. Be sure to first consult with a qualified financial adviser and/or tax professional before implementing any strategy discussed herein. Upon request, the advisor will provide a list of all recommendations made during the past twelve months. Past performance is not indicative of future performance.